Cargando…

Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma

Triple‐hit lymphoma (THL), which is classified into high‐grade B‐cell lymphoma with rearrangements of MYC, BCL2 and BCL6, presents aggressive biological behaviour. High‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto‐HSCT) is considered to be one of the recomme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Junnan, Zhang, Yizhuo, Ding, Sa, Yasheng, Kalbinur, Li, Yueyang, Yu, Yong, Wang, Yafei, Tian, Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581337/ https://www.ncbi.nlm.nih.gov/pubmed/34698437 http://dx.doi.org/10.1111/jcmm.16999

Ejemplares similares

Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients
por: Tian, Chen, et al.
Publicado: (2021)

Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma
por: Tian, Chen, et al.
Publicado: (2020)

Chidamide in the treatment of peripheral T-cell lymphoma
por: Chan, Thomas S, et al.
Publicado: (2017)

A novel conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan in the autologous stem cell transplantation of aggressive T-cell lymphoma
por: Zeng, Qiang, et al.
Publicado: (2023)

Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
por: Guan, Xu-Wen, et al.
Publicado: (2020)

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
por: Li, Xinyang, et al.
Publicado: (2022)

Flow Cytometric Evaluation of Double/Triple Hit Lymphoma
por: Roth, Christine G., et al.
Publicado: (2016)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia
por: Chen, Kai, et al.
Publicado: (2020)

Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens
por: Zhang, Fangwen, et al.
Publicado: (2019)

Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study
por: Chen, Xinrui, et al.
Publicado: (2021)

Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report
por: Wang, Xing-Tong, et al.
Publicado: (2020)

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
por: Shi, Yuankai, et al.
Publicado: (2017)

Triple hit effect
por: Dixit, Ramakant, et al.
Publicado: (2015)

Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens
por: Kim, Heyjin, et al.
Publicado: (2020)

Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma
por: Wang, Jinni, et al.
Publicado: (2022)

The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review
por: Ridwansyah, Hastono, et al.
Publicado: (2023)

The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study
por: Zhang, Wei, et al.
Publicado: (2021)

A modified regimen of low-dose rituximab therapy for patients with refractory immune thrombocytopenia associated with systemic lupus erythematosus
por: Zhang, Shuo, et al.
Publicado: (2021)

Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab
por: Marcacci, Gianpaolo, et al.
Publicado: (2021)

Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study
por: Ma, Qianwen, et al.
Publicado: (2019)

Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome
por: Dodero, Anna, et al.
Publicado: (2021)

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
por: Gui, Lin, et al.
Publicado: (2021)

P1201: A REAL-WORLD STUDY OF CHIDAMIDE FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA IN CHINA
por: Wang, Xin, et al.
Publicado: (2023)

Isolated orbital mass as the primary presentation of a triple-hit lymphoma transformed from a systemic follicular lymphoma
por: Zhou, Xiao Yi, et al.
Publicado: (2018)

Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: A case report and literature review
por: Jin, Jingxia, et al.
Publicado: (2018)

Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide
por: Chen, Jinghong, et al.
Publicado: (2023)

Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy
por: Campi, Irene, et al.
Publicado: (2022)

Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies
por: Du, Ying, et al.
Publicado: (2022)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B‐Cell lymphoma ‐results of a single center, retrospective cohort in China
por: Wang, Yawen, et al.
Publicado: (2022)

Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma
por: Li, Shaoying, et al.
Publicado: (2016)

Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions
por: Alaibac, Mauro
Publicado: (2018)

Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting
por: Zhao, Jiangning, et al.
Publicado: (2012)

Comparison of chemotherapy regimens plus rituximab in adult Burkitt lymphoma: A single-arm meta-analysis
por: Lu, Xiaoxuan, et al.
Publicado: (2022)

Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance
por: Baysal, Mehmet, et al.
Publicado: (2020)

Secondary skin involvement in gastric diffuse large B-cell lymphoma treated with chidamide: A case report
por: Yang, Dan, et al.
Publicado: (2018)

Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma
por: Xue, Kai, et al.
Publicado: (2021)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
por: Liu, Weiping, et al.
Publicado: (2021)

Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy
por: Hao, Yuan-Yuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k58p2kfrr1uipjkipg784eerrj